141080.KQ
LigaChem Biosciences Inc.
KOE · Healthcare · Biotechnology · KR
KRW 88,300.00
−2.75%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 98.8B | 141.6B | 125.9B | 34.1B | 33.4B |
| Cost of Revenue | 15.8B | 19.2B | 15.9B | 16.3B | 17.6B |
| Gross Profit | 83.0B | 122.4B | 109.9B | 17.8B | 15.8B |
| Operating Expenses | |||||
| R&D Expense | 275.3B | 216.9B | 113.2B | 79.6B | 55.7B |
| SG&A Expense | 10.8B | 6.3B | 8.2B | 5.1B | 2.2B |
| General & Admin Expense | 2.2B | 2.6B | 1.3B | 1.2B | 745.6M |
| Selling & Marketing Expense | 2.0B | 3.7B | 6.9B | 4.0B | 1.4B |
| Other Expenses | 2.7B | 5.8B | 9.5B | 2.5B | 442.5M |
| Total Operating Expenses | 288.8B | 229.0B | 130.9B | 98.6B | 70.9B |
| Cost and Expenses | 304.5B | 248.0B | 146.8B | 115.0B | 88.4B |
| Operating Income (EBIT) | (205.8B) | (106.5B) | (20.9B) | (80.8B) | (55.0B) |
| Non-Operating | |||||
| Interest Income | 15.4B | 18.4B | 20.0B | 5.8B | 4.3B |
| Interest Expense | 2.2B | 883.2M | 503.2M | 528.3M | 285.8M |
| Net Interest Income | 13.2B | 17.5B | 19.5B | 5.3B | 4.0B |
| Other Non-Op Income/Expense | 21.2B | 12.6B | 30.0B | 5.1B | 975.6M |
| Non-Operating Income (excl Interest) | (14.7B) | — | (30.5B) | (4.8B) | (1.3B) |
| EBT (Pre-Tax Income) | (184.6B) | (93.9B) | 9.1B | (75.7B) | (47.8B) |
| Income Tax Expense | (3.2B) | (2.3B) | 1.3B | (2.0B) | (2.6B) |
| Bottom Line | |||||
| Net Income | (178.7B) | (74.3B) | 7.8B | (73.7B) | (45.1B) |
| Earnings from Cont. Ops | (181.4B) | (91.6B) | 7.8B | (73.7B) | (45.1B) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (196.0B) | (74.3B) | 7.8B | (73.7B) | (45.1B) |
| Per Share | |||||
| Basic EPS | (₩5,352) | (₩2,042) | ₩227 | (₩2,595) | (₩1,851) |
| Diluted EPS | (₩5,352) | (₩2,042) | ₩224 | (₩2,595) | (₩1,851) |
| Revenue Per Share | ₩2,684 | ₩3,867 | ₩3,656 | ₩1,202 | ₩1,371 |
| Shares | |||||
| Basic Shares Outstanding | 36.8M | 36.6M | 34.4M | 28.4M | 24.4M |
| Diluted Shares Outstanding | 36.8M | 36.6M | 34.8M | 28.4M | 24.4M |
| Profitability Metrics | |||||
| EBITDA | (191.3B) | (100.1B) | 14.6B | (71.4B) | (43.4B) |
| D&A | 6.8B | 6.6B | 5.0B | 4.7B | 4.1B |
| EBIT | (198.0B) | (106.5B) | 9.6B | (76.1B) | (47.4B) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026